白细胞介素-35的生物活性及其在类风湿关节炎中的研究进展被引量：3

导出

摘要 IL-35是近几年发现的新型细胞因子，2007年Collison等和Niedbala等2个研究小组分别在Natu陀和Eur J Immunol发表了有关IL-35的文章，并阐述了其生物功能。随后越来越多的研究证实其在炎症性、肿瘤性、自身免疫病中发挥着重要的作用。且有研究表明，IL-35可抑制关节炎症的进展，阻止关节的破坏，本文就IL-35的生物活性及其在RA中的研究进展作以综述。

作者常玲徐建华肖会

机构地区安徽医科大学第一附属医院风湿免疫科

出处《中华风湿病学杂志》 CAS CSCD 北大核心 2016年第4期268-270,共3页 Chinese Journal of Rheumatology

基金国家自然科学基金（81302587）

关键词类风湿关节炎生物活性白细胞介素 IL-35 自身免疫病细胞因子生物功能关节炎症

分类号 R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献25

1Collison LW, Workman C J, Kuo 3q', et al. The inhibitory tokine IL-35 contributes to regulatory T-cell function[J]. Nat 2007, 450(22) : 566-569. DOI: 10.1038/nature06306.
2Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Thl7 cells [J]. Eur J Immunol, 2007, 37 (11): 3021-3029. DOI: 10.1002/ eji.200737810.
3V ignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers [J]. Nat Immunol, 2012, 13 (8): 722-728. DOI: 10.1038/ni.2366.
4Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling ff the IL-35 receptor are unconventional [J]. Nat Immunol, 2012, 13(3): 290-299. DOI: 10.1038/ni.2227.
5Niedobitek G, Pazolt D, Teichmann I, et al. Frequent expression tff the Epstein-Barr virus(EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells[J]. J Pathol, 2002, 198(3): 310-316. DOI: 10.1002/path. 1217.
6Bardel E, Larousserie F, Charlot-Rabiega P, et al. Human CD4+ CD25+Foxp3 regulatory T cells do not constitutively express IL-35{J]. J Immunol, 2008, 181(10): 6898-6905. DOI: 10. 4049/jimmunol. 181.10.6898.
7Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive anti-inflammatory cytokine: a new system of categorizing anti- inflammatory eytokines[J]. PLoS One, 2012, 7(3): e33628. DOI: 10.1371/journal.pone.O033628.
8Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulatory B cells that suppress CNS autoimmune disease[J]. Nat Med, 2014, 20(6): 633-641. DOI: 10.1038/nm.3554.
9Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases[J]. Nature, 2014, 507 (7492) : 366-370. DOI: lO.1038/nature12979.
10Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38[J]. Joint Bone Spine, 2013, 80 (5): 449-453. DOI: 10.1016/j. jbspin.20 3.04.014.

二级参考文献37

1Beyer M,Schultze JL. Regulatory T cells in cancer. Blood,2006, 108(3):804-311.
2Bilate AM, Lafaille JJ. Induced CD4 + Foxp3 + regulatory T cellsin immune tolerance. Annu Rev Immunol,2012, 30:733-758.
3Facciabene A, Motz GT, Coukos G. T-regulatory cells: key play-ers in tumor immune escape and angiogenesis. Cancer Res, 2012,72(9):2162-2171.
4Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cyto-kine IL-35 contributes to regulatory T-cell function. Nature,2007 , 450(7169) :566-569.
5Niedbala W, Wei XQ,Cai B, et al. IL-35 is a novel cytokinewith therapeutic effects agmnst collagen-induced arthritis throughthe expansion of regulatory T cells and suppression of Thl7 cells.EurJ Immunol, 2007, 37( 11) :3021-3029.
6Allan SE,Song-Zhao GX, Abraham T, et al. Inducible repro-gramming of human T cells into Treg cells by a conditionally activeform of FOXP3. Eur J Immunol, 2008, 38(12) :3282-3289.
7Ning-Wei Z. Interleukin (IL)-35 is raising our expectations. RevMed Chil, 2010, 138(6) :758-766.
8Kochetkova I,Golden S, HoMemess K, et al. IL-35 stimulationof CD39 + regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol, 2010,I84(12):7144-7153.
9Olson BMf Jankou.ka-Can E, Becker JT,et al. Human prostate tumoranti^n-specific CD8 + r^ulatory T cells are inhibited by CTLA-4 orIL-35 blockade. J Immunol,2012,189(12) :5590-5601.
10Wang Z, Liu JQ, Liu Z,et al. Tumor-derived IL-35 promotestumor growth by enhancing myeloid cell accumulation and angio-genesis. J Immunol, 2013, 190(5) ;2415-2423.